{"filings":[{"id":501837,"accession_number":"0001193125-26-229173","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2026-05-18T21:30:08+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cullinan reports initial Phase 1 data for CLN-978: B cell depletion and early efficacy in RA/SLE","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["As of Jan 14, 2026 cutoff, 14 patients dosed (5 RA, 9 SLE) across cohorts 1-3.","B cell depletion >75% in 9/11 patients after 10 mcg; 3/6 below quantification after 20 mcg.","4/5 RA patients had DAS28-ESR decrease from high activity to moderate/remission.","5/6 SLE patients had SLEDAI score decrease >4 points; ultrasound synovitis improved in 3/4 RA.","CLN-978 well tolerated; dose escalation continues; updated data at EULAR June 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95479,"accession_number":"0001193125-26-210290","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cullinan Therapeutics Q1 net loss $49.7M, cash $393.3M; zipalertinib NDA accepted with PDUFA Feb 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $49.7M for Q1 2026 vs $48.5M in Q1 2025; R&D expense $42.1M, G&A $11.6M.","Cash and investments $393.3M as of March 31, 2026; runway into 2029 under current plan.","FDA accepted NDA for zipalertinib in EGFR ex20ins NSCLC; PDUFA target date February 27, 2027.","Initial CLN-978 SLE and RA data to be presented at EULAR June 6, 2026; multi-dose RA data due Q3 2026.","Velinotamig initial SLE data expected Q4 2026; CLN-049 RP2D and AML update planned by Q4 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108594,"accession_number":"0001193125-26-099355","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2026-03-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cullinan reports $439M cash, $219.9M net loss; CLN-978 data and zipalertinib NDA on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments of $439.0M as of Dec 31, 2025; runway into 2029.","Net loss of $50.7M in Q4 2025 ($219.9M full year), vs $47.6M in Q4 2024.","Initial clinical data for CLN-978 in SLE and RA confirmed for Q2 2026; repeat dosing data in RA in Q3 2026.","Zipalertinib rolling NDA submission completed; REZILIENT3 frontline study enrollment completed, top-line results by year-end 2026.","Cullinan eligible for $30M upon 2L U.S. approval, up to $100M upon 1L, plus 50/50 profit share."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108593,"accession_number":"0001193125-26-006998","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Cullinan reports $439M cash as of Dec 31, 2025; outlines 2026 clinical milestones for CLN-978, CLN-049, zipalertinib","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash, equivalents, investments, interest receivable $439.0M at Dec 31, 2025; runway into 2029.","CLN-978: Phase 1 dose escalation in RA, SLE, SjD ongoing; initial data readouts in Q2/Q3/Q4 2026.","CLN-049: Fast Track for relapsed/refractory AML; dose expansion to determine RP2D in Q4 2026; pivotal trial expected.","Zipalertinib: NDA submission completion expected Q1 2026; REZILIENT3 enrollment complete H1 2026; $130M US milestones + 50% profit share.","Velinotamig: Genrix Bio Phase 1 in China initiated; initial data in Q4 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125038,"accession_number":"0001193125-25-310764","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cullinan Therapeutics reports 31% CR/CRh rate at 12 µg/kg for CLN-049 in R/R AML Phase 1","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["At 12 µg/kg (n=16), CR/CRh rate 31% (5/16) and CRc rate 31% (5/16); at ≥6 µg/kg (n=32), CR/CRh 25% and CRc 28%.","In TP53-mutated AML patients at 12 µg/kg, 50% (4/8) achieved CR/CRh; 3 of 4 responses durable >16 weeks.","63% (5/8) of responders at ≥6 µg/kg had response >16 weeks; 2 patients proceeded to transplant.","Safety: CRS mostly Grade 1/2 (35.6%), no Grade 3 with two step-up doses; no discontinuations due to CRS.","FDA granted Fast Track designation; dose escalation continues with expansion cohorts planned early 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125037,"accession_number":"0001193125-25-291448","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2025-11-21T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Cullinan Therapeutics terminates exclusive MIT license for CLN-617; program abandoned","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminates Exclusive Patent License Agreement with MIT for CLN-617, effective Feb 18, 2026.","Decision based on not pursuing further development of CLN-617 cancer immunotherapy.","Company will return licensed patent rights for CLN-617 technology to MIT.","CLN-617 was an exclusive worldwide license for a cancer immunotherapy product."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125036,"accession_number":"0001193125-25-268041","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Cullinan Q3 net loss $50.6M; focuses on T cell engagers; cash runway into 2029","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $50.6M vs $40.6M YoY; R&D expense $42.0M, G&A $13.6M.","Cash & investments $475.5M at Sept 30, 2025; runway expected into 2029.","CLN-049 showed ~30% CRc in R/R AML; oral presentation at ASH 2025.","CLN-978 initial SLE & RA safety/B-cell data expected H1 2026.","Discontinued CLN-619 and CLN-617; partner Taiho plans NDA for zipalertinib by year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125035,"accession_number":"0001193125-25-261799","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cullinan reports Phase 1 CLN-049 data: 31% CRc at 12 μg/kg in r/r AML","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Anti-leukemic activity at doses ≥6 μg/kg: CRc 30%, ORR 57% (n=23); at 12 μg/kg CRc 31%, ORR 69% (n=13).","Responses across genetic risk; in TP53-mutated AML 4/5 patients responded (2 CRh, 2 MLFS) at 12 μg/kg.","Safety manageable: all CRS Grade 1-2; no discontinuations due to CRS or ICANS. Common TEAEs: CRS 40%, IRR 35%.","Oral presentation at ASH on Dec 8, 2025; dose escalation ongoing. Company to host investor event Dec 8."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141731,"accession_number":"0000950170-25-112949","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2025-09-04T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cullinan Therapeutics revises CLN-978 SLE data timing to H1 2026","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Initial clinical data for CLN-978 in systemic lupus erythematosus now expected in first half of 2026.","Timelines for all other pipeline programs remain unchanged.","Updated corporate presentation posted to company website; no other changes disclosed in filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141730,"accession_number":"0000950170-25-104547","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Cullinan Q2 net loss $70.1M, cash $510.9M; appoints new directors; CLN-978 enrolling","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2025 net loss $70.1M vs $42.0M; R&D expenses $61.0M vs $36.3M; cash and investments $510.9M providing runway into 2028.","Board changes effective Aug 7: Anne-Marie Martin and David Ryan resigned; Mittie Doyle and Andrew Allen appointed as Class I and II directors, respectively.","CLN-978 Phase 1 studies in SLE, RA, and Sjögren's actively enrolling; initial SLE safety and B cell depletion data expected Q4 2025.","Velinotamig (BCMAxCD3 T cell engager) in-licensed from Genrix Bio for $20M upfront; up to $692M in milestones plus tiered royalties.","Partner Taiho plans to submit NDA for zipalertinib in relapsed EGFR ex20ins NSCLC by end of 2025 based on REZILIENT1 pivotal data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159635,"accession_number":"0000950170-25-085425","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Cullinan Therapeutics annual meeting results: all proposals pass, directors elected","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Class II directors: Anthony Rosenberg, David P. Ryan, Mary Thistle; each received >47M votes for.","Ratified KPMG as independent auditor for FY2025: 51.9M for, 157K against, 14K abstain.","Approved advisory say-on-pay on executive compensation: 46.96M for, 2.00M against, 14.7K abstain.","Stockholders voted for annual say-on-pay frequency (48.5M for 1 year); board adopts annual vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159634,"accession_number":"0000950170-25-081601","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Cullinan licenses BCMAxCD3 bispecific velinotamig from Genrix for $20M upfront, up to $692M milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront license fee of $20 million; Genrix eligible for up to $292M in development/regulatory milestones and up to $400M in sales-based milestones.","Tiered royalties on ex-Greater China net sales ranging from mid-single digit to mid-teens percent.","Velinotamig has shown potential best-in-class efficacy in ~50 relapsed/refractory multiple myeloma patients; Cullinan to develop in autoimmune diseases.","Genrix plans Phase 1 autoimmune study in China by end of 2025; Cullinan will conduct global development after that.","Cullinan reiterates cash runway into 2028 based on current operating plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159633,"accession_number":"0000950170-25-066382","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cullinan Q1 net loss $48.5M; CLN-978 gains EMA approval for RA, expands into Sjögren's","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $48.5M in Q1 2025 vs $37.1M in Q1 2024; R&D expenses rose to $41.5M.","Cash and investments $567.4M as of March 31, 2025; runway into 2028 reaffirmed.","EMA approved Phase 1 study of CLN-978 in active, difficult-to-treat rheumatoid arthritis; to start Q2 2025.","CLN-978 Phase 1 in Sjögren's disease to initiate in U.S. in Q2 2025; SLE data expected Q4 2025.","CLN-619 discontinued in gynecological cancers; zipalertinib REZILIENT1 results at ASCO June 1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178008,"accession_number":"0000950170-25-028343","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cullinan Therapeutics reports Q4/FY 2024 results; zipalertinib pivotal study met endpoint","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments of $606.9M at Dec 31, 2024; runway extended into 2028.","Net loss of $47.6M in Q4 2024 (vs $23.8M Q4 2023); FY 2024 net loss $167.4M (vs $153.2M).","R&D expenses $40.5M Q4 2024 (vs $34.8M); G&A $14.6M (vs $10.6M) year-over-year.","Zipalertinib Phase 2b met primary endpoint (ORR); full results mid-2025; NDA submission planned H2 2025.","Initial CLN-978 SLE data expected Q4 2025; CLN-619 endometrial/cervical cancer data expected Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178007,"accession_number":"0000950170-25-010199","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2025-01-29T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cullinan's zipalertinib meets primary endpoint in Phase 2b NSCLC trial; H2 2025 FDA submission planned","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["REZILIENT1 trial met primary endpoint of overall response rate in NSCLC with EGFR exon 20 insertion mutations after prior therapy.","Safety profile generally consistent with previous data presentations; full results to be submitted for upcoming medical conference.","Pending FDA discussions, companies plan to submit for U.S. regulatory approval in second half of 2025.","Zipalertinib (CLN-081/TAS6417) is a monotherapy for patients who have received prior therapy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194696,"accession_number":"0000950170-24-122778","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cullinan Therapeutics Q3 net loss $40.6M; cash $639M; CLN-978 IND cleared for SLE Phase 1","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $40.6M ($0.69/sh) vs $39.2M ($0.91/sh) in Q3 2023; cash $639M provides runway to 2028.","CLN-978 (SLE) IND cleared in US and Australia; Phase 1 starts; initial data expected Q4 2025.","Zipalertinib pivotal Phase 2b enrollment completed ahead of schedule; results mid-2025.","CLN-619 expansion data in endometrial/cervical cancers expected Q2 2025; patent issued to 2041.","R&D expense $35.5M, G&A $13.3M; both increased YoY from $33.8M and $11.0M respectively."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194695,"accession_number":"0000950170-24-114841","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2024-10-16T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cullinan Therapeutics receives FDA IND clearance for CLN-978 in moderate-to-severe SLE","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared IND for CLN-978, a CD19 T cell engager, in systemic lupus erythematosus.","Phase 1 trial will enroll patients with SLEDAI score ≥8 and inadequate response to ≥2 prior treatments.","Starting dose 10 mcg; Part A dose escalation, Part B dose expansion with multiple schedules.","First development-stage CD19 T cell engager to receive FDA IND clearance in autoimmune diseases.","Global trial already cleared in Australia (NCT06613360); U.S. enrollment now allowed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210998,"accession_number":"0000950170-24-107011","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2024-09-17T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cullinan Therapeutics receives Australian HREC approval to start Phase 1 SLE trial of CLN-978","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["HREC approval in Australia to initiate global Phase 1 trial of CLN-978 for systemic lupus erythematosus (SLE).","CLN-978 is a CD19xCD3 bispecific T cell engager designed for off-the-shelf access and convenient dosing.","SLE affects ~430,000 people globally; current treatments rarely induce treatment-free remission.","Company also submitted IND to U.S. FDA for this study on September 16, 2024.","Trial will assess safety, pharmacokinetics, and initial clinical activity in multiple countries."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210997,"accession_number":"0000950170-24-093314","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cullinan Q2 net loss $42M; cash $664.9M; advancing CLN-978 IND in SLE for Q3 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $42.0M vs $32.2M Q2 2023; R&D $36.3M, G&A $13.8M; cash runway into 2028.","CLN-978 (CD19xCD3 T cell engager) IND for SLE on track for Q3 2024; pursuing RA with FAU Erlangen & Università Cattolica.","CLN-619 combo data at ASCO showed objective responses in oncogenic mutation NSCLC; expansion cohorts added.","Positive initial zipalertinib data from REZILIENT1 study; ESMO presentation planned.","Discontinued CLN-418; returned rights to Harbour BioMed. Oversubscribed PIPE raised $280M in April."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.61,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229477,"accession_number":"0000950170-24-078554","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2024-06-27T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Cullinan Therapeutics stockholders elect Anne-Marie Martin and David Meek as directors, ratify KPMG as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Anne-Marie Martin elected with 25,054,060 votes for, 11,471,277 withheld, 4,156,894 broker non-votes.","David Meek elected with 36,409,849 votes for, 115,488 withheld, 4,156,894 broker non-votes.","KPMG LLP ratified as independent auditor for FY2024 with 40,163,993 for, 516,975 against, 1,263 abstentions.","Annual meeting held June 26, 2024; no other proposals were considered."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229476,"accession_number":"0000950170-24-067662","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cullinan reports Phase 2b zipalertinib data: 39% ORR in post-amivantamab NSCLC patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ORR of 39% (confirmed) and DCR of 94% in 18 evaluable patients; median DOR and PFS not yet reached.","No grade 4 or 5 treatment-related adverse events; safety profile manageable and consistent with prior data.","Data cut-off Jan 12, 2024; patients received median 3 prior therapies including chemo, anti-PD1/L1, and EGFR TKI.","Enrollment in pivotal REZILIENT1 trial (Modules B2 and C) on track to complete by end of 2024.","Partnership with Taiho: upfront $275M plus up to $130M in milestones; 50/50 US profit share."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229475,"accession_number":"0000950170-24-064025","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2024-05-23T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cullinan announces CLN-619+Keytruda shows PRs in EGFR/ALK NSCLC; monotherapy CR in parotid","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Combination with pembrolizumab: 3 confirmed PRs in NSCLC (EGFR/ALK) and gastric patients typically CPI-unresponsive.","Monotherapy: 1 CR (mucoepidermoid parotid, 71 wks), 2 PRs (endometrial), 9 SD ≥18 wks; clinical benefit rate 41.4%.","Safety profile well tolerated; most TRAEs grade 1/2; no treatment-related deaths.","Based on data, expansion cohorts in NSCLC initiated; Phase 1 in relapsed/refractory multiple myeloma planned.","Data to be presented at ASCO 2024 on June 3; investor event June 1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229474,"accession_number":"0000950170-24-060481","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Cullinan Q1 net loss $37.3M; cash $434.8M; plans CLN-978 autoimmune IND Q3 2024; Meek appointed director","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents, investments $434.8M as of March 31, 2024; plus $280M April private placement extends cash runway into 2028.","Q1 net loss $37.3M vs $58.1M Q1 2023; R&D expenses $30.6M, G&A $12.3M.","CLN-978 development pivoted to autoimmune diseases; IND for SLE expected Q3 2024; B-NHL study discontinued.","David Meek appointed to board effective May 15; Thomas Ebeling to resign June 26.","Initial CLN-619 combination & monotherapy data to be presented at ASCO June 1, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229473,"accession_number":"0000950170-24-049436","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2024-04-29T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Cullinan Therapeutics hires Mary Kay Fenton as CFO; $495k salary, 200k-share option grant","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mary Kay Fenton appointed CFO effective April 29, 2024; previously CFO of Talaris Therapeutics.","Annual base salary set at $495,000; target annual bonus of 40% of base salary.","Received option to purchase 200,000 shares vesting over 4 years (25% one-year cliff).","Severance: 9 months base salary plus prorated bonus if terminated without cause or for good reason outside CIC period.","No familial relationship with directors/officers; at-will employment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229472,"accession_number":"0000950170-24-044593","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2024-04-16T23:59:59+00:00","items":["1.01","3.02","5.03","7.01","8.01","9.01"],"status":"ready","headline":"Cullinan raises $280M, pivots to autoimmune with promising CLN-978 data; cash runway into 2028","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["$280M private placement at $19/share; pre-funded warrants $18.999; extends cash runway into 2028.","Strategic pivot to autoimmune diseases; first indication systemic lupus erythematosus (SLE); IND planned Q3 2024.","CLN-978 Phase 1 B-NHL data: 1 complete response, rapid B cell depletion, low-grade CRS, no ICANS.","Name change to Cullinan Therapeutics (Nasdaq: CGEM); reflects expanded focus beyond oncology.","Enrollment in B-NHL study discontinued to focus on autoimmune development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248029,"accession_number":"0000950170-24-031140","cik":1789972,"company_name":"Cullinan Therapeutics, Inc.","ticker":"CGEM","form_type":"8-K","filed_at":"2024-03-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cullinan Oncology reports Q4 2023 net loss of $25.6M; CFO Trigilio to depart Mar 29","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for FY 2023 was $155.1M vs income of $109.2M in 2022; Q4 loss $25.6M.","Cash and investments $468.3M; runway expected into H2 2026.","On track to report CLN-619 combo/monotherapy data at a medical meeting in Q2 2024.","Received FDA IND clearance for CLN-619 in multiple myeloma; exploring CLN-978 in autoimmune diseases.","CFO Jeff Trigilio to depart effective March 29, 2024, with transition support."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":962125737.4455541,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}